This study aims to investigate the effects of small interference RNA (siRNA) targeting PML-RARα mRNA on the activity of the acute promyelocytic leukemia cell line NB4. The proliferation inhibition was evaluated by MTT assay and colony-formation inhibiting test. Apoptosis was determined by flow cytometry after siRNA treatment. The results showed that the cell growth of siRNA treated group was inhibited, and the apoptosis of NB4 could be induced. The siRNA targeting PML-RARα mRNA might be a valid therapy of acute promyelocytic leukemia.
Citation：
LUOHaixi, PANYanpeng, HAOXinbao, CAOXianying. Effect of siRNA Targeting PML-RARα Fusion Gene on Activity of the Acute Promyelocytic Leukemia Cell Line NB4. Journal of Biomedical Engineering, 2014, 31(4): 850-854. doi: 10.7507/1001-5515.20140160
Copy
Copyright © the editorial department of Journal of Biomedical Engineering of West China Medical Publisher. All rights reserved
| 1. |
WANG Z Y, CHEN Z. Acute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008, 111(5): 2505-2515.
|
| 2. |
DE STANCHINA E, QUERIDO E, NARITA M, et al. PML is a direct p53 target that modulates p53 effector functions[J]. Mol Cell, 2004, 13(4): 523-535.
|
| 3. |
马军.三氧化二砷治疗急性早幼粒细胞白血病的回顾及进展[J].国际输血及血液学杂志,2007,30(3):210-213.
|
| 4. |
CEJKA D, LOSERT D, WACHECK V. Short interfering RNA (siRNA):tool or therapeutic?[J]. Clin Sci (Lond), 2006, 110(1): 47-58.
|
| 5. |
孙关林.急性早幼粒细胞白血病治疗的进展[J].白血病·淋巴瘤,2006,15(6):401-404.
|
| 6. |
周建军,乐秀芳,韩家娴,等.评价抗癌物质活性的改良MTT方法[J].中国医药工业杂志,1993,24(10):455-457.
|
| 7. |
于文强,孙秉中,陈竺.基因反义核酸与全反式维A酸对早幼粒白血病细胞株作用比较[J].解放军医学杂志,1998,23(1):23-25.
|
| 8. |
陈烨,缪金明,朱学宏,等.抗PML-RARα反义核酸的设计、合成和对NB4细胞生长、凋亡的影响[J].中华血液学杂志,1999,20(6):303-305.
|
| 9. |
SHEGOKAR R, AL SHAAL L, MISHRA P R. SiRNA delivery: challenges and role of carrier systems[J]. Pharmazie, 2011, 66(5): 313-318.
|
| 10. |
VAISHNAW A K, GOLLOB J, GAMBA-VITALO C, et al. A status report on RNAi therapeutics[J]. Silence, 2010, 1(1):1-14.
|
| 11. |
WATTS J K, COREY D R. Clinical status of duplex RNA[J]. Bioorg Med Chem Lett, 2010, 20(11): 3203-3207.
|
- 1. WANG Z Y, CHEN Z. Acute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008, 111(5): 2505-2515.
- 2. DE STANCHINA E, QUERIDO E, NARITA M, et al. PML is a direct p53 target that modulates p53 effector functions[J]. Mol Cell, 2004, 13(4): 523-535.
- 3. 马军.三氧化二砷治疗急性早幼粒细胞白血病的回顾及进展[J].国际输血及血液学杂志,2007,30(3):210-213.
- 4. CEJKA D, LOSERT D, WACHECK V. Short interfering RNA (siRNA):tool or therapeutic?[J]. Clin Sci (Lond), 2006, 110(1): 47-58.
- 5. 孙关林.急性早幼粒细胞白血病治疗的进展[J].白血病·淋巴瘤,2006,15(6):401-404.
- 6. 周建军,乐秀芳,韩家娴,等.评价抗癌物质活性的改良MTT方法[J].中国医药工业杂志,1993,24(10):455-457.
- 7. 于文强,孙秉中,陈竺.基因反义核酸与全反式维A酸对早幼粒白血病细胞株作用比较[J].解放军医学杂志,1998,23(1):23-25.
- 8. 陈烨,缪金明,朱学宏,等.抗PML-RARα反义核酸的设计、合成和对NB4细胞生长、凋亡的影响[J].中华血液学杂志,1999,20(6):303-305.
- 9. SHEGOKAR R, AL SHAAL L, MISHRA P R. SiRNA delivery: challenges and role of carrier systems[J]. Pharmazie, 2011, 66(5): 313-318.
- 10. VAISHNAW A K, GOLLOB J, GAMBA-VITALO C, et al. A status report on RNAi therapeutics[J]. Silence, 2010, 1(1):1-14.
- 11. WATTS J K, COREY D R. Clinical status of duplex RNA[J]. Bioorg Med Chem Lett, 2010, 20(11): 3203-3207.
